Pharmaceuticals

A partnership between NSA Labs and Proscia is slashing study times for brain research, showing how digital platforms are key to finding new therapies faster.

A new oral drug from Nimbus Therapeutics uses AI-driven precision to fight inflammation and repair tissue, offering new hope for millions with IBD.

Cyrano Therapeutics' CYR-064 shows promise in a Phase 2 study, potentially becoming the first approved drug for persistent post-viral smell loss.

With demand for freeze-drying surging, OFD adds project management veteran Danielle Grosso to its expanding leadership team to scale operations.

An independent board again backs the safety of BriaCell's metastatic breast cancer therapy in a pivotal Phase 3 trial, boosting hope for a new treatment.

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

With a massive dataset from $6.2B in prior authorizations, SamaCare's AI is speeding up access to critical drugs, but raises questions about market power.

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

New long-term data shows duvakitug maintained remission in IBD patients for nearly a year, positioning it as a top contender in a new class of therapy.

A new partnership combines AI design with rapid lab testing to crack the code of complex proteins, speeding up drug discovery and opening new frontiers.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

A new study uses PET-CT scans to track CIT-013, a first-in-class antibody targeting the root cause of inflammation in rheumatoid arthritis and HS.

A Swedish biotech and Belgian university secure major EU funding to advance a first-in-class drug against glioblastoma, a notoriously deadly brain tumor.

With a novel glutamate-targeting drug and a €38M cash injection, Newron aims to transform care for treatment-resistant schizophrenia.